{"id":49911,"date":"2022-10-21T15:02:48","date_gmt":"2022-10-21T13:02:48","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/"},"modified":"2022-10-21T15:02:48","modified_gmt":"2022-10-21T13:02:48","slug":"renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/","title":{"rendered":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET"},"content":{"rendered":"
\n

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae<\/sup>) therapy platform, today announced that the Company\u2019s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th<\/sup> at 1 p.m. ET. To register for the event please visit RenovoRx Fireside Chat Registration<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nDuring the webinar, Mr. Bagai will discuss the company\u2019s mission to become a leading provider in oncology therapy by disrupting standard of care (intravenous systemic chemotherapy) treatment of difficult-to-treat cancers, and how its unique RenovoTAMP therapy platform offers an innovative approach to delivering targeted chemotherapy to tumors. The goals of the RenovoTAMP therapy platform are to improve quality of life for patients living with difficult-to-treat cancer by reducing the debilitating side effects typical of standard of care chemotherapy treatment and to extend patient survival. Additionally, Mr. Bagai will review the Company\u2019s pivotal Phase 3 TIGeR-PaC clinical trial which has its first interim analysis targeted for reporting in the fourth quarter of this year. The webinar is open to the public and participants will have an opportunity to ask questions during the Q&A portion of the webinar.\n<\/p>\n

\nROTH Capital Deep Dive Webinar
\n
<\/b>Format:<\/b> Webinar
\n
Host:<\/b> Scott Henry, CFA \u2013 Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research and the Medical Technology sector at ROTH Capital Partners
\n
Participant:<\/b> Shaun Bagai, CEO
\n
Date and Time:<\/b> Thursday, October 27th<\/sup> at 1:00 p.m. ET
\n
Register:<\/b> RenovoRx Fireside Chat Registration<\/a>\n<\/p>\n

\nFor additional information please contact KCSA Strategic Communications by emailing RenovoRx@KCSA.com<\/a>.\n<\/p>\n

\nAbout RenovoRx, Inc.
\n
<\/b>RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae<\/sup>) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx\u2019s lead product candidate, RenovoGem\u2122, is a combination of gemcitabine and our patented delivery system, RenovoCath\u00ae<\/sup>, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.\n<\/p>\n

\nRenovoRx\u2019s patent portfolio for its therapy platform and product candidates includes seven U.S. patents, one European patent and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer.\n<\/p>\n

\nRenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards \u2013 Life Sciences Edition 2020 for its RenovoTAMP technology.\n<\/p>\n

\nLearn more by visiting the RenovoRx website<\/a> or following us on Facebook<\/a>, LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nCompany Contact:<\/b>
RenovoRx, Inc.
\n
Shaun R. Bagai, CEO
\n
James Ahlers, CFO<\/p>\n

Investor Contact:<\/b>
KCSA Strategic Communications
\n
Valter Pinto or Jack Perkins
\n
T: 212-896-1254
\n
renovorx@kcsa.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae) therapy platform, today announced that the Company\u2019s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49911","6":"format-standard","7":"category-industry"},"yoast_head":"\nRenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae) therapy platform, today announced that the Company\u2019s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-21T13:02:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET\",\"datePublished\":\"2022-10-21T13:02:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/\"},\"wordCount\":514,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005058\\\/en\\\/1609647\\\/21\\\/logo-simple-final-NEWCOLORS-2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/\",\"name\":\"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005058\\\/en\\\/1609647\\\/21\\\/logo-simple-final-NEWCOLORS-2.jpg\",\"datePublished\":\"2022-10-21T13:02:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005058\\\/en\\\/1609647\\\/21\\\/logo-simple-final-NEWCOLORS-2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221021005058\\\/en\\\/1609647\\\/21\\\/logo-simple-final-NEWCOLORS-2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/","og_locale":"en_US","og_type":"article","og_title":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend","og_description":"LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP\u00ae) therapy platform, today announced that the Company\u2019s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-21T13:02:48+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET","datePublished":"2022-10-21T13:02:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/"},"wordCount":514,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/","url":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/","name":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg","datePublished":"2022-10-21T13:02:48+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221021005058\/en\/1609647\/21\/logo-simple-final-NEWCOLORS-2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/renovorx-to-participate-in-roth-capital-deep-dive-webinar-on-october-27-2022-at-100-p-m-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49911"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49911\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}